(Moderator) Jahan Marcu, PhD- Endocannabinoid System in Disease
Sue Sisley, MD - PTSD and Veterans
Dustin Sulak, DO - Clinical Cannabinoid Medicine: Successes and Challenges
Marcel Bonn-Miller, PhD - Marijuana and PTSD: Existing Evidence and New Directions
Michelle Sexton PhD - Observational Research and the PROMIS Toolkit
Marcel O. Bonn-Miller, Ph. D., is a Research Health Science Specialist at the National Center for PTSD and Center for Innovation to Implementation at the VA Palo Alto Health Care System as well as Center of Excellence in Substance Abuse Treatment and Education at the Philadelphia VAMC, and Adjunct Assistant Professor in the Department of Psychiatry at the University of Pennsylvania Perelman School of Medicine. He received his B.A. and Ph.D. in Clinical Psychology from the University of Vermont and was a Postdoctoral Fellow at Stanford University School of Medicine. Dr. Bonn-Miller has dedicated his career to understanding the interrelations between cannabis use and PTSD symptomatology, with the aim of informing intervention and prevention strategies. Dr. Bonn-Miller is internationally recognized as a leading expert in the study of cannabis use among individuals with PTSD. He has served as PI or Co-I on dozens of grants varying in focus from experimental laboratory-controlled to prospective outcome studies, including a VA Career Development Award. Approximately 50 of his 98 peer-reviewed empirical publications have investigated cannabis comorbidity, most with a focus on PTSD.
Jahan Marcu, Ph. D., is currently the Senior Scientist and Chief Auditor for Americans for Safe Access and the Patient Focused Certification (PFC) Program. His is also on the Board of Directors of the International Association for Cannabinoids as Medicine (IACM). Dr. Marcu is the Director of Research and Development at Green Standard Diagnostics Inc. He received his Ph.D. for significant contributions to the study of the structure and function of the CB1 receptor, and the role of the endocannabinoid system in bone. Before earning his Ph.D., Dr. Marcu worked at the California Pacific Medical Center Research Institute studying the anti-cancer properties of compounds from the cannabis plant (Published in the Journal of Molecular Cancer Therapeutics) and on analytical Cannabis research projects in Holland. He is also an author of the American Herbal Pharmacopeia's Cannabis Monograph and one of the auditors for the Patient Focused Certification (PFC) program; an enforcement and oversight program that ensures that basic product safety protocols are followed at Cannabis operations. Dr. Marcu is a recipient of the Billy Martin research award from the International Cannabinoid Research Society.
Dr. Michelle Sexton is a Naturopathic Doctor and Executive Medical Research Director at the Center for the Study of Cannabis and Social Policy. She is the Founder and Chief Science Officer of Phytalab, the first WA State Cannabis testing facility. She was a paid contractor for the WSLCB to develop the laboratory certification process for I502. Dr. Sexton is a technical advisor and editor on the Cannabis Monograph, adopted for quality control guidance for I502 Cannabis. She is internationally known for her work, research, patient advocacy and industry leadership.
Dr. Suzanne A. Sisley practices medicine in Scottsdale, AZ and specializes in Internal Medicine and Psychiatry. She is widely known for her research into potential medical uses of marijuana to treat veterans diagnosed with PTSD. Dr. Sisley's research is supported by the Multidisciplinary Association for Psychedelic Studies (MAPS), a California-based nonprofit organization.
Dr. Dustin Sulak is an integrative medicine pioneer with a focus in osteopathy, mind-body medicine, and medical cannabis. Dr. Sulak received undergraduate degrees in nutrition science and biology from Indiana University, a doctorate of osteopathy from the Arizona College of Osteopathic Medicine, and completed an internship at Maine-Dartmouth Family Medicine Residency. Mentored by Andrew Weil, M.D. during his training, Dr.Sulak's clinical practice focuses on treating refractory conditions in adults and children with a variety of safe, alternative therapies in an individualized, health-centered approach.